P53与MITF/Bcl-2被确定为NRAS突变黑色素瘤对MEK抑制获得性耐药的关键通路
在NRAS突变黑色素瘤细胞中,MEK抑制剂(pimasertib)显著抑制增殖但凋亡作用有限,与MITF系统性上调及MITF/Bcl-2抗凋亡信号激活相关。Bcl-2选择性抑制(ABT-199)或CRISPR/Cas9敲除Bcl-2可消除获得性耐药并恢复对MEK抑制的敏感性;直接再激活p53(PRIMA-1Met、APR-246)同样打破耐药并与MEK抑制协同诱导大量凋亡。
要点
- MEK抑制(pimasertib)显著抑制NRAS突变黑色素瘤细胞增殖,但对凋亡作用有限。
- 获得性耐药与MITF/Bcl-2抗凋亡信号强烈激活相关。
- ABT-199抑制Bcl-2或CRISPR/Cas9敲除Bcl-2可消除获得性耐药并恢复MEK抑制敏感性。
核心结论
- MITF/Bcl-2是NRAS突变黑色素瘤细胞对MEK抑制剂凋亡作用产生耐药的关键机制。
- Bcl-2抑制或p53再激活可打破获得性耐药并与MEK抑制协同诱导凋亡,为预防或逆转抗MEK耐药提供有前景的联合方案。
研究设计与样本
- 在Q61NRAS突变黑色素瘤细胞 panel 中开展体外研究,评估MEK抑制(pimasertib)对增殖与凋亡的影响。
- 通过环磷酸腺苷激活模拟MITF效应、ABT-199选择性抑制Bcl-2、CRISPR/Cas9敲除Bcl-2及PRIMA-1Met(APR-246)再激活p53进行干预。
主要发现
- MEK抑制(pimasertib)显著抑制细胞增殖,但对凋亡作用有限,可由MITF系统性上调解释。
- 通过环磷酸腺苷激活模拟MITF效应可赋予对MEK抑制的耐药并上调Bcl-2表达。
- 获得性耐药与抗凋亡信号MITF/Bcl-2的强烈激活相关。
- ABT-199抑制Bcl-2或CRISPR/Cas9敲除Bcl-2可消除获得性耐药并恢复NRAS突变黑色素瘤细胞对MEK抑制的敏感性。
- PRIMA-1Met(APR-246)直接再激活p53可打破耐药,并与MEK抑制协同在野生型或突变型p53的NRAS突变黑色素瘤细胞中诱导大量凋亡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Activating mutations in Neuroblastoma RAS viral oncogene homolog (NRAS) are found in 15-30% of melanomas and are associated with a poor prognosis. Although MAP kinase kinase (MEK) inhibitors used as single agents showed a limited clinical benefit in patients with NRAS-mutant melanoma due to their rather cytostatic effect and high toxicity, their combination with other inhibitors of pathways known to cooperate with MEK inhibition may maximise their antitumour activity. Similarly, in a context where p53 is largely inactivated in melanoma, hyperexpression of Microphthalmia associated transcription factor (MITF) and its downstream anti-apoptotic targets may be the cause of the restraint cytotoxic effects of MEK inhibitors. Indeed, drug combinations targeting both mutant BRAF and MITF or one of its important targets Bcl-2 were effective in mutant BRAF melanoma but had no effect on acquired resistance. Therefore, we aimed to further investigate the downstream MITF targets that can explain this anti-apoptotic effect and to evaluate in parallel the effect of p53 reactivation on the promotion of apoptosis under MEK inhibition in a panel of Q61NRAS-mutant melanoma cells. First, we showed that MEK inhibition (pimasertib) led to a significant inhibition of cell proliferation but with a limited effect on apoptosis that could be explained by the systematic MITF upregulation. Mimicking the MITF effect via cyclic adenosine monophosphate activation conferred resistance to MEK inhibition and upregulated Bcl-2 expression. In addition, acquired resistance to MEK inhibition was associated with a strong activation of the anti-apoptotic signalling MITF/Bcl-2. More importantly, selective Bcl-2 inhibition by ABT-199 or Bcl-2 knockout using CRISPR/Cas9 system annihilated the acquired resistance and restored the sensitivity of NRAS-mutant melanoma cells to MEK inhibition. Strikingly and similarly, direct p53 reactivation (PRIMA-1Met, APR-246) also broke resistance and synergised with MEK inhibition to induce massive apoptosis in NRAS-mutant melanoma cells with wild-type or mutant p53. Hence, our data identify MITF/Bcl-2 as a key mechanism underlying resistance of NRAS-mutant melanoma cells to apoptosis by MEK inhibitors and paves the way for a promising drug combination that could prevent or reverse anti-MEK resistance in this group of patients.
引用
- Najem A, Krayem M, Salès F, et al. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. Eur J Cancer. 2017. PMID: 28738256. doi:10.1016/j.ejca.2017.06.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。